In an accelerated decisio | Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med Hernexeos from Boehringer Ingelheim.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or metastatic…
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with…
In a landmark moment for its oncology ambitions, GSK has
Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second…
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase (HDAC)…
